# US 2020/0368327 A1 · Methods for preparing modified von willebrand factor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0368327 A1
- Document ID: US20200368327A1
- Status: Published application
- Kind: A1
- Application number: 16/925,411
- Filed: 2020-07-10
- Published: 2020-11-26
- Earliest claimed: 2015-05-22
- Assignees: Csl Behring Lengnau AG
- Applicants: CSL Behring Lengnau AG
- Inventors: Stefan SCHULTE; Hans-Wilhelm BELTZ; Sabine PESTEL; Thomas WEIMER; Matthias PELZING
- Web page: https://patentgrep.com/patent/US20200368327A1

## CPC

- A61K 38/37: Factors VIII
- A61K 38/1741: {alpha-Glycoproteins}
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- C07K 14/473: {alpha-Glycoproteins}
- C07K 14/755: Factors VIII {, e.g. factor VIII C (AHF), factor VIII Ag (VWF)}
- G01N 30/96: using ion-exchange (G01N30/02, G01N30/90 take precedence)
- C07K 2319/02: containing a signal sequence
- C07K 2319/31: fusions, other than Fc, for prolonged plasma life, e.g. albumin
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention provides modified von Willebrand Factor molecules, methods for their preparation and uses thereof. The invention further provides pharmaceutical compositions for treating coagulation disorders.

## Claims

### Claim at position 1

-21. (canceled)

### Claim 22

A method of treating a blood coagulation disorder, comprising administering to a subject in need thereof an effective amount of a glycoprotein and an effective amount of a Factor VIII (FVIII),
wherein the glycoprotein comprises a truncated von Willebrand Factor (VWF) capable of binding to the FVIII,
wherein the glycoprotein comprises N-glycans, wherein i) at least 75% of the N-glycans comprise at least one sialic acid moiety, ii) less than 35% of the N-glycans comprise two or more terminal and non-sialylated galactose residues, and/or iii) less than 6% of the N-glycans comprise three or more terminal and non-sialylated galactose residues,
wherein the glycoprotein is administered intravenously or subcutaneously, and
wherein the FVIII is administered intravenously or subcutaneously.

### Claim 23 (depends on 22)

The method according to claim 22, wherein the mean residence time (MRT) of the FVIII is increased and/or the clearance of the FVIII is decreased by co-administration of the glycoprotein, as compared to a treatment with FVIII alone; and/or wherein the frequency of administration of the FVIII is reduced as compared to a treatment with FVIII alone.

### Claim 24 (depends on 22)

The method of claim 22, wherein the glycoprotein and the FVIII are administered simultaneously.

### Claim 25 (depends on 22)

The method of claim 22, wherein the glycoprotein and the FVIII are administered separately and sequentially.

### Claim 26 (depends on 22)

The method of claim 22, wherein at least 70% of the N-glycans comprise at least one α-2,6-sialic acid moiety or at least one α-2,3-sialic acid moiety.

### Claim 27 (depends on 22)

The method of claim 22, wherein at least 80% of the N-glycans comprise at least one sialic acid moiety.

### Claim 28 (depends on 22)

The method of claim 22, wherein at least 85% of the N-glycans comprise at least one sialic acid moiety.

### Claim 29 (depends on 22)

The method of claim 22, wherein the truncated VWF comprises (a) amino acids 776 to 805 of SEQ ID NO:9, or (b) an amino acid sequence having at least 90% sequence identity to amino acids 776 to 805 of SEQ ID NO:9.

### Claim 30 (depends on 22)

The method of claim 22, wherein the truncated VWF consists of (a) amino acids 776 to 805 of SEQ ID NO:9, or (b) an amino acid sequence having at least 90% sequence identity to amino acids 764 to 1242 of SEQ ID NO:9

### Claim 31 (depends on 22)

The method of claim 22, wherein the truncated VWF comprises (a) amino acids 764 to 1242 of SEQ ID NO:9, or (b) an amino acid sequence having at least 90% sequence identity to amino acids 764 to 1242 of SEQ ID NO:9.

### Claim 32 (depends on 22)

The method of claim 22, wherein the truncated VWF consists of (a) amino acids 764 to 1242 of SEQ ID NO:9, or (b) an amino acid sequence having at least 90% sequence identity to amino acids 764 to 1242 of SEQ ID NO:9.

### Claim 33 (depends on 22)

The method of claim 22, wherein a half-life extending heterologous polypeptide is fused to the truncated VWF, and/or a half-life extending moiety is conjugated to the glycoprotein.

### Claim 34 (depends on 22)

The method of claim 22, wherein the glycoprotein is a dimer.

### Claim 35 (depends on 34)

The method of claim 34, wherein the affinity of the dimeric glycoprotein to FVIII is greater than the affinity of the corresponding monomeric glycoprotein to FVIII.
